国内心、脑、肿瘤放射性诊断药物研究进展  

Domestic Advances in Brain,Heart,and Tumor Radioactive Diagnosis Drugs

作　　者：曾华辉[1] 张华北[1] 

机构地区：[1]放射性药物教育部重点实验室北京师范大学化学学院,北京100875

出　　处：《化学进展》2011年第7期1485-1492,共8页Progress in Chemistry

摘　　要：近年来,我国放射性药物的发展很迅速,并且在医学诊治疾病中及基础研究中占据越来越重要的地位。放射性诊断药物是指用于体内进行医学诊断的含放射性核素标记的化合物或生物制剂。本文介绍了国内近年放射性诊断药物在神经系统、心血管、肿瘤等方面的研究进展和应用前景,并提出了目前国内放射性药物研究存在的主要问题和今后可能的发展方向:大力发展PET药物,重点是设计和研制各类脑受体显像剂、有特异性受体结合的肿瘤显像剂和心肌代谢显像剂等。In recent years,radiopharmaceuticals have played an increasingly important role in medical diagnosis and treatment of diseases and fundamental research of medicine with the rapid development of radiopharmaceuticals.A diagnosis radiopharmaceutical is a biological agent or small molecule labeled with radioactive nuclide,which is applied in medical diagnosis of diseases in vivo.In this paper,a brief introduction to recent domestic development and applications of diagnosis radiopharmaceuticals in nervous system,cardiovascular and tumor imaging is given.Some main existing problems in the research of radiopharmaceuticals and the new research aspects may be provided in the coming years are presented.We should devote major efforts to developing PET tracers,and the key aspect is to design and develop all kinds of brain receptor imaging agents,receptor binding tumor imaging agents,myocardium metabolism imaging agents and so on.These developments and achievements of radiopharmaceuticals to improve the people＇s health are highly significant in our country.

关 键 词：放射性药物 显像剂 诊断 治疗 放射性药物 PET 

分 类 号：O615.4[理学—无机化学] R817[理学—化学]